Related Experiment Videos
Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in
R Berecz1, A LLerena, A de la Rubia
1University of Extremadura, Faculty of Medicine, Department of Pharmacology and Psychiatry, Unit of Research and Clinical Psychopharmacology, Mérida Psychiatric Hospital, Badajoz, Spain.
Pharmacopsychiatry
|January 9, 2003
Summary
The risperidone/9-hydroxy-risperidone ratio reflects cytochrome P450 CYP2D6 enzyme activity in schizophrenia patients. This ratio can help predict drug interactions and optimize risperidone treatment for better patient outcomes.
Area of Science:
- Pharmacogenetics
- Clinical Pharmacology
- Psychiatry
Background:
- Cytochrome P450 CYP2D6 enzyme activity influences risperidone metabolism.
- Individuals with impaired CYP2D6 activity (poor metabolizers) may experience higher risperidone plasma concentrations.
- Understanding CYP2D6 activity is crucial for personalized antipsychotic dosing.
Purpose of the Study:
- To investigate the relationship between debrisoquine metabolic ratio (MR), a CYP2D6 activity marker, and risperidone plasma levels in schizophrenic patients.
- To assess the impact of CYP2D6 inhibitors on risperidone pharmacokinetics.
- To evaluate the utility of the risperidone/9-hydroxy-risperidone ratio as a marker of CYP2D6 activity.
Main Methods:
- Studied 40 Spanish and Hungarian schizophrenic patients.
- Measured debrisoquine metabolic ratio (MR) as a marker for CYP2D6 activity.
- Analyzed risperidone and 9-hydroxy-risperidone plasma levels, calculating the risperidone/9-hydroxy-risperidone ratio.
- Assessed CYP2D6 inhibition in patients co-medicated with CYP2D6 inhibitors.
Main Results:
- A significant correlation was found between the risperidone/9-hydroxy-risperidone ratio and debrisoquine MR (p < 0.001).
- Patients co-medicated with strong CYP2D6 inhibitors showed higher risperidone plasma levels and risperidone/9-hydroxy-risperidone ratios compared to monotherapy patients.
- Debrisoquine MR was also significantly higher in patients co-medicated with strong CYP2D6 inhibitors (p < 0.01).
Conclusions:
- The risperidone/9-hydroxy-risperidone ratio effectively reflects in vivo CYP2D6 enzyme activity.
- This ratio can aid in identifying potential pharmacokinetic interactions involving risperidone.
- Utilizing the risperidone/9-hydroxy-risperidone ratio may improve the optimization of risperidone treatment in psychiatric patients.